In a recent study posted to the bioRxiv* preprint server, researchers assessed the impact of gene amplification on cross-species adaptation.
Study: Gene amplification acts as a molecular foothold to facilitate cross-species adaptation and evasion of multiple antiviral pathways. Image Credit: Billion Photos/Shutterstock
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Spillover events between different species have often initiated various pandemics throughout human history. However, further research is necessary to understand the evolutionary forces that drive such cross-species transmissions.
About the study
In the present study, the team demonstrated the incidence of gene amplification of RhTRS1 could effectively rescue viral replication in fibroblasts of partially resistant African green monkeys (AGMs).
The team infected A549 cells with either the vaccinia virus (VACV)+RhTRS1 or the VACV strain named Copenhagen, expressing a beta-galactosidase (bg) reporter gene. Furthermore, the team infected an A549 protein kinase R (PKR) knockout (KO) cell line. The team also investigated if the rhtrs1 phenotype was consistently present in other human-derived cells by infecting A549 cells with VACV-bg, VACV+RhTRS1, AGM-A, AGM-B, or AGM-C.
Furthermore, the team explored whether the rhtrs1 amplification could increase the extent of viral replication in PKR’s absence. This was achieved by infecting both PKR A549 cells as well as PKR-competent cells with the AGM-A, AGM-B, and AGM-C viral populations. The viral titers of the infected cells were then compared with those observed in the VACV-RhTRS1 and VACV-bg infected cells. Subsequently, the team conducted an immunoblot analysis on intermediates derived from the PKR pathways in the infected A549 cells.
The team also investigated the role of ribonuclease L (RNase L) in the restriction of VACV-RhTRS1 replication within human cells by infecting A549 or A549 PKR cells with VACV-RhTRS1, VACV-bg, or AGM-A. The infected cells were then tested for products of ribonucleic acid (RNA) degradation 24 hours after infection. The team also infected either RNase L-competent A549 cells or clustered regularly interspaced short palindromic repeats (CRISPR)-mediated deletion of RNase L present in existing A549 cells with VACV-RhTRS1, VACV-bg, or AGM-A.
Results
The study results showed that A549 cells restricted VACV+RhTRS1 replication by almost 10000 times as compared to the replication of VACV-bg. The team noted that the deletion of A549 PKR cells enhanced the replication of VACV+RhTRS1 almost 1000 times compared to the PKR-competent cells. On the other hand, VACV+RhTRS1 cells could replicate almost 100 times less in comparison to the wild-type (WT) virus present in the PKR cells. Duplication of rhtrs1 also elicited the benefit of partial replication in human foreskin fibroblasts (HFF) cells.
VACV-bg, VACV+RhTRS1, and the AGM-adapted populations comprise an amplification related to the rhtrs1 locus and unique arrays corresponding to single nucleotide polymorphisms (SNP) present at various allelic frequencies among different populations. The team noted that the AGM-adapted virus displayed replication 100 to 1000 times more than that observed in VACV-RhTRS1 cells but 100 to 1000 times lesser than VACV-bg found in the A549 cells.
Furthermore, the team observed that PKR KO did not provide additional benefits related to viral replication to either of the three AGM-adapted viruses since they replicated up to titers almost 100 times lower than those noted in VACV-bg infected cells. This suggested that rhtrs1 amplification could fully inhibit PKR.
Interestingly, the VACV-bg infected cells displayed minimal eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation and no PKR phosphorylation while the VACV+RhTRS1 cells showed high levels of eIF2α and PKR phosphorylation. The AGM-A infected cells had PKR phosphorylation, while the AGM-A infected A549 cells also displayed eIF2α phosphorylation. This suggested that AGM-adapted viruses did not fully cause inhibition of human PKR even though PKR KO did not positively affect the replication of AGM-A viruses. Altogether, this indicated that PKR was not the sole host factor that restricted the replication of VACV+RhTRS1 in human cells.
The team observed that RNAase had no impact on the replication of VACV-bg. However, VACV-RhTRS1 replicated almost 1000 times more in A549 RNase L cells than in A549 cells. However, VACV-RhTRS1 replication was 100 times lower than that in titers of the A549 PKR cells.
Serial passaging of viruses from primary HFF cells revealed a ten-time increase in titers for the HFF-Ap2, HFF-Bp2, and HFF-Cp2 viral populations. This increase was found to be consistently stable for six rounds of passage. In the seventh serial passage, each viral population displayed a gradual increase in viral titers. This overall increase in viral replication remained mostly stable in the three viral populations through the 12 serial passages.
Overall, the study findings showed that initial adaptation elicited by genetic amplification acted as a molecular foothold in enhancing the viral population among resistant host species.
This news article was a review of a preliminary scientific report that had not undergone peer-review at the time of publication. Since its initial publication, the scientific report has now been peer reviewed and accepted for publication in a Scientific Journal. Links to the preliminary and peer-reviewed reports are available in the Sources section at the bottom of this article. View Sources
Article Revisions
- May 13 2023 - The preprint preliminary research paper that this article was based upon was accepted for publication in a peer-reviewed Scientific Journal. This article was edited accordingly to include a link to the final peer-reviewed paper, now shown in the sources section.
Epigenetic silencing of BEND4 unveils new path for PDAC treatment